Shares of Gland Pharma rallied 11.06% to an intraday high of ₹2,075 during Monday's trading session following the company's robust Q4 FY26 results. According to reports from The Economic Times, the pharmaceutical company's strong performance was driven by significant growth in its CDMO business and improved operational efficiency across key markets.
Gland Pharma delivered exceptional financial results for Q4 FY26, with consolidated net profit surging 97% year-on-year to ₹366.7 crore compared to ₹186.5 crore in the corresponding quarter last year. As reported by The Economic Times, revenue from operations increased 22% YoY to ₹1,742.8 crore, against ₹1,424.9 crore reported in Q4 FY25. The company's adjusted EBITDA for the quarter rose 51% year-on-year, while the adjusted EBITDA margin improved to 30%.
The Contract Development and Manufacturing Organization (CDMO) business emerged as a major growth driver, contributing 46% of total revenues during Q4 FY26 and recording strong 36% YoY growth. According to The Economic Times, for the full FY26 period, CDMO revenues also contributed 46% of total sales and grew 28% year-on-year. The company continued strengthening its product pipeline through sustained research investments, with quarterly R&D spending at ₹506 million and full-year FY26 R&D investments reaching ₹2,230 million.
The Board of Directors recommended a final dividend of ₹20 per equity share (2000%) on the face value of ₹1 each for FY26, subject to shareholder approval at the company's 48th Annual General Meeting. As reported by The Economic Times, the dividend is expected to be paid within 30 days from the date of approval. Executive Chairman Mr. Srinivas Sadu commented on the results, highlighting the company's 14.5% consolidated revenue growth and 26% adjusted EBITDA margin for FY26, supported by robust CDMO segment growth and new product launches.
From a technical perspective, the stock's 14-day Relative Strength Index (RSI) stands at 57.3, indicating neutral-to-positive momentum. According to The Economic Times, the stock is trading above all 8 out of 8 key simple moving averages, signaling continued bullish momentum. On the valuation front, the stock trades at a price-to-earnings (PE) ratio of 36.33 and a price-to-book (PB) ratio of 3.36.
